Brain metastases, also called metastatic brain tumors, are cancerous growths that arise when cancer cells travel through the bloodstream or lymphatic system from a primary tumor elsewhere in the body and establish themselves in brain tissue. They are among the most common neurological complications of systemic cancer, and their management is one of the most active areas in neuro-oncology. When a metastasis is large or causing symptoms, surgical removal is often the first step. But surgery alone cannot guarantee that every malignant cell has been eliminated. Microscopic deposits of tumor cells frequently remain in the margins of the resection cavity and in the surrounding brain parenchyma, invisible to imaging and inaccessible to the surgeon’s instruments. Left untreated, these residual cells can seed a local recurrence, forcing patients into further interventions and eroding neurological function and quality of life.

To address that residual disease, radiation therapy after surgery has long been a standard of care. The most precise form of this treatment is stereotactic radiosurgery, a technique that uses three-dimensional imaging to map the target with millimeter accuracy and deliver highly concentrated doses of radiation from multiple angles. Despite its name, radiosurgery involves no incision; instead, intersecting radiation beams converge on the target so that the tumor receives a lethal dose while the surrounding healthy tissue is spared as much exposure as possible. Historically, this treatment has been delivered in a single session, exploiting the sharp dose falloff that stereotactic planning makes possible. Yet even with this precision, clinical experience has shown that about 30 to 40 percent of patients develop recurrence at the surgical site despite single-fraction treatment, a figure that has motivated researchers to reconsider the fundamental assumptions of postoperative radiation.

The biological rationale for dividing the dose rests on a well-established principle of radiation physics and radiobiology known as the therapeutic ratio. When radiation is split into multiple treatments delivered over days or weeks, clinicians can escalate the total dose administered to the target volume. Normal brain tissue has a capacity for repair between fractions, and the intervals between treatments allow healthy cells to recover from sublethal DNA damage. Tumor cells, by contrast, generally lack the same repair efficiency, particularly when their DNA repair machinery is already compromised by the mutations that drove their malignancy. Fractionation also exploits the cell cycle: cells are most radiosensitive during certain phases, and spreading treatment across time increases the probability that tumor cells will be caught in a vulnerable state. The result is a widening of the gap between the dose that eradicates tumor and the dose that harms normal tissue.

Previous retrospective studies had suggested that fractionated stereotactic radiosurgery could improve local control after surgery, but retrospective designs are vulnerable to selection bias, and the approach had never been validated in a randomized clinical trial, the gold standard for establishing treatment efficacy. The new multicenter study was designed to close that gap. The trial enrolled 242 patients with one to four brain metastases, each of whom had at least one metastasis larger than 2 centimeters that had been surgically removed. Patients were randomly assigned to receive either a single session of stereotactic radiosurgery or fractionated stereotactic radiosurgery delivered in three or five treatments. Radiation doses were calibrated to the size of the treatment area, reflecting the reality that larger treatment volumes tolerate less radiation per session. Importantly, brain metastases that had not been surgically removed were treated according to the same schedule assigned to each patient, allowing the investigators to assess the effect of fractionation on intact tumors as well.

The results, reported after a median follow-up of four years, showed a clear advantage for the fractionated approach. One year after treatment, 87 percent of patients who received fractionated stereotactic radiosurgery had no recurrence at the surgical site, compared with 81 percent of those who received a single treatment. Fractionated radiosurgery also better controlled brain metastases that had not been surgically removed, although that secondary result did not reach statistical significance. The most consequential finding, however, concerned survival. Median overall survival was 29 months for patients treated with fractionated radiosurgery, compared with 20 months for those who received a single fraction, translating into a 31 percent lower risk of death associated with the divided treatment schedule. In a disease setting where median survival has historically been measured in months, a nine-month difference in median survival is a clinically meaningful advance.

Paul D. Brown, a radiation oncologist at Mayo Clinic Comprehensive Cancer Center and co-principal investigator of the study, said the findings provide the evidence necessary to transform clinical practice, allowing physicians to offer patients a treatment that controls their disease and is associated with improved survival. He explained that the survival benefit was unexpected and that while the exact mechanism remains unclear, the investigators suspect that advances in systemic therapies over the past decade may be interacting with better control of disease within the brain to produce overall better outcomes for patients. This hypothesis reflects a broader shift in oncology: as targeted therapies and immunotherapies extend systemic disease control, the brain increasingly becomes the site where treatment success or failure is decided, making local intracranial control a critical determinant of long-term survival.

Equally important for patients and clinicians, the trial found no difference in side effects or complications between the two treatment approaches. This safety profile matters because a common concern with fractionated postoperative radiosurgery has been the potential for increased toxicity to the brain, including radiation necrosis, a delayed injury to brain tissue that can cause swelling and neurological symptoms. The absence of a measurable difference in adverse events between the arms suggests that the additional dose delivered through fractionation comes without a detectable cost in tolerability, strengthening the case for adopting the divided schedule as a new standard. Robert Mutter, chair of research in the Department of Radiation Oncology and co-leader of the Novel Therapeutics and Therapeutic Modalities Research Program at Mayo Clinic Comprehensive Cancer Center, described the trial as practice-changing, demonstrating that fractionated radiosurgery not only reduces recurrence after surgery for large brain metastases but may also improve overall survival.

The implications of the trial extend beyond the immediate question of fractionation schedules. For patients with metastatic cancer, the brain has long been a sanctuary site where many drugs penetrate poorly and where uncontrolled disease often determines prognosis. By showing that a simple change in how postoperative radiation is delivered can extend survival, the study reinforces the principle that meticulous local therapy remains essential even in an era of powerful systemic agents. It also provides a template for future trials: the randomized design, the stratification of treated and untreated lesions within the same patients, and the size-based dose assignment all offer a rigorous framework for answering similar questions about other combinations of surgery, radiation, and drug therapy. As the results move from the meeting hall into clinical guidelines, patients undergoing surgery for brain metastases can expect their radiation oncologists to weigh a divided course of radiosurgery as the evidence-based default, a shift that could translate into more months of meaningful life for thousands of people each year.

Subject of Research: Fractionated versus single-fraction stereotactic radiosurgery after surgery for brain metastases

Article Title: Study finds fractionated radiosurgery reduces recurrence after surgery for brain metastases, may improve survival

Article References: Study finds fractionated radiosurgery reduces recurrence after surgery for brain metastases, may improve survival. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: brain metastases, stereotactic radiosurgery, fractionated radiation, radiation oncology, Mayo Clinic, randomized clinical trial, cancer recurrence, overall survival, ASTRO, postoperative radiation, neuro-oncology, local control